Supply Lenvatinib Mesylate CAS 857890-39-2

Model NO.
py0993
Colour
White
Standard
USP Bp Ep
Transport Package
25kg/Drum
Specification
99%
Trademark
Puya
Origin
China
Production Capacity
10ton/Year
Reference Price
$ 72.00 - 162.00
Contact Us

Product Description

 Lenvatinib Mesylate CAS 857890-39-2
Product Name: lenvatinib Mesylate
Synonyms: lenvatinib Methanesulfonate;E7080 Mesylate;4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide monomethanesulfonate;4-[3chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate;CAT#A863437;Lenvatinib Mesylate,Amadis Chemical offer CAS#857890-39-2;lenvatinib Mesylate;E7080;E-7080;E 7080
CAS: 857890-39-2
MF: C22H23ClN4O7S
MW: 522.95862
EINECS: 812-398-0


Lenvatinib Mesylate is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well.
Everolimus is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR).

Function
Lenvatinib Mesylate is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well.
It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.
It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.




 

 

Organic Intermediate